Want to see VVOS full AI Analyst Report?
VVOS Stock Chart & Stats
$0.39
<$0.01(2.52%)
At close: 4:00 PM EDT
$0.39
<$0.01(2.52%)
Day’s Range― - ―
52-Week Range$0.36 - $5.21
Previous CloseN/A
Volume131.13K
Average Volume (3M)421.86K
Market Cap
$5.70M
Enterprise Value$27.30
Total Cash (Recent Filing)$2.11M
Total Debt (Recent Filing)$12.27M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 19, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding13,894,600
10 Day Avg. Volume324,525
30 Day Avg. Volume421,860
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-14.00
Price to Sales (P/S)1.20
P/FCF Ratio-1.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.93Price Target Upside393.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.39
Revenue Forecast (FY)$23.25M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth And Margin ExpansionRobust top-line growth paired with a 10-point gross margin gain indicates the core treatment and services mix can scale with attractive product-level economics. Durable margin expansion suggests structural improvements in revenue mix and higher-margin service offerings that support long-term profitability if scale continues.
Rising Patient Volumes And Provider ProductivityA large increase in patient appointments and improved provider conversion metrics reflect stronger clinical adoption and practice-level productivity. These durable operational gains imply the company can generate more revenue per provider and replicate efficiency across practices as training scales.
Strategic Acquisitions And Partnerships Expanding ServicesThe SCN acquisition and new physician-aligned ventures broaden service offerings into diagnostics and integrated care, shifting revenue toward higher-margin clinical services. This structural move diversifies revenue streams and creates referral pathways that can sustain growth and improve long-term contribution margins.
Bears Say
Severely Weakened Balance SheetNegative equity and meaningful debt materially limit financial flexibility, increase the risk of covenant/default outcomes, and constrain investments. Over the medium term, this capital-structure weakness raises reliance on dilutive equity or onerous debt restructurings to sustain operations and meet listing requirements.
Persistent Cash Burn And Low LiquiditySustained negative operating cash flow and a very small cash balance force repeated external financing. Reliance on capital raises or debt exchanges to fund working capital is a structural risk that can hamper execution, dilute shareholders, and interrupt growth initiatives if markets tighten or financing terms worsen.
High Operating Losses And Rising G&ALarge operating deficits and sharply higher G&A point to structural operating leverage challenges. Until fixed costs are controlled or revenue scale sufficiently offsets SG&A, profitability will remain elusive, increasing the probability that future growth will be funded at the expense of margins or equity dilution.
Vivos Therapeutics News
VVOS FAQ
What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $0.36 and its highest was $5.21 in the past 12 months.
What is Vivos Therapeutics’s market cap?
Vivos Therapeutics’s market cap is $5.70M.
When is Vivos Therapeutics’s upcoming earnings report date?
Vivos Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 14 days.
How were Vivos Therapeutics’s earnings last quarter?
Currently, no data Available
Is Vivos Therapeutics overvalued?
According to Wall Street analysts Vivos Therapeutics’s price is currently Undervalued.
Does Vivos Therapeutics pay dividends?
Vivos Therapeutics does not currently pay dividends.
What is Vivos Therapeutics’s EPS estimate?
Vivos Therapeutics’s EPS estimate is -0.41.
How many shares outstanding does Vivos Therapeutics have?
Vivos Therapeutics has 13,894,600 shares outstanding.
What happened to Vivos Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vivos Therapeutics?
Currently, no hedge funds are holding shares in VVOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivos Therapeutics
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
VVOS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted very strong top-line momentum—70% year-over-year revenue growth, 34% sequential growth, a 10 percentage-point gross margin improvement and rapidly rising patient volumes and KPIs driven by the SCN acquisition and provider productivity gains. However, these operational gains were offset by substantial increases in G&A and cash burn, a low cash balance (~$2.1M), increased discounts reducing product revenue, and an explicit need for additional financing and debt restructuring. Management presented multiple high-margin initiatives (pediatrics, insomnia services, medical affiliations) that could materially improve profitability, but near-term execution and capital availability remain material risks.View all VVOS earnings summariesVVOS Stock 12 Month Forecast
Average Price Target
$1.93
▲(393.59% Upside)
Technical Analysis
Iridex
―
Co-Diagnostics
―
Adagio Medical Holdings
―
Envoy Medical
―
Nexalin Technology, Inc.
―
Ownership Overview
9.74% Insiders
2.26% Mutual Funds
0.36% Other Institutional Investors
87.20% Public Companies and
Individual Investors